20 results
8-K
EX-99.1
NMRD
Nemaura Medical Inc
13 Nov 23
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
4:15pm
of the program in various territories.
Financial Summary:
Research and development (“R&D”) expenses were $491,803 and $257,061 for the three months ended
424B8
NMRD
Nemaura Medical Inc
11 Sep 23
Prospectus unintentially filed late
4:41pm
research and development
Prior year true-up of NOL’s
Other
Change in valuation allowance
R&D credit received
Actual income tax benefit
The tax
8-K
EX-99.1
bl81ea2os
14 Aug 23
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update
8:30am
POS AM
kb1 62cqj
3 Aug 23
Prospectus update (post-effective amendment)
4:08pm
424B4
bxap8helu7wpf l8
15 May 23
Prospectus supplement with pricing info
4:31pm
- Prev
- 1
- Next